A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma Horwitz, S. M., Feldman, T. A., Hess, B. T., Khodadoust, M. S., Kim, Y. H., Munoz, J., Patel, M. R., Phillips, T. J., Smith, S. D., Smith, S. M., Wilcox, R. A., Birrell, M. R., Leeds, J. M., Conley, P. B., Michelson, G. C., Coffey, G. P., Curnutte, J. T., Hamlin, P. A. AMER SOC HEMATOLOGY. 2019

View details for DOI 10.1182/blood-2019-123986

View details for Web of Science ID 000518218500569